CA2705373A1 - Hiv-1 envelope glycoprotein oligomer and methods of use - Google Patents
Hiv-1 envelope glycoprotein oligomer and methods of use Download PDFInfo
- Publication number
- CA2705373A1 CA2705373A1 CA2705373A CA2705373A CA2705373A1 CA 2705373 A1 CA2705373 A1 CA 2705373A1 CA 2705373 A CA2705373 A CA 2705373A CA 2705373 A CA2705373 A CA 2705373A CA 2705373 A1 CA2705373 A1 CA 2705373A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- fusion polypeptide
- fusion
- r2gp140
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
- C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98728707P | 2007-11-12 | 2007-11-12 | |
| US60/987,287 | 2007-11-12 | ||
| PCT/US2008/083190 WO2009102357A2 (en) | 2007-11-12 | 2008-11-12 | Hiv-1 envelope glycoprotein oligomer and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2705373A1 true CA2705373A1 (en) | 2009-08-20 |
Family
ID=40957413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2705373A Abandoned CA2705373A1 (en) | 2007-11-12 | 2008-11-12 | Hiv-1 envelope glycoprotein oligomer and methods of use |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8597658B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2235065A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2011502521A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008350273B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2705373A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009102357A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2877205A4 (en) * | 2012-07-26 | 2016-04-06 | Jackson H M Found Military Med | VACCINE WITH A MULTIMED FUSION PROTEIN AND IMMUNOTHERAPY |
| CN109153704A (zh) * | 2016-05-02 | 2019-01-04 | 斯克里普斯研究学院 | 与hiv-1免疫原相关的组合物和方法 |
| AU2018366480C1 (en) * | 2017-11-17 | 2024-02-01 | Grifols Diagnostic Solutions Inc. | Novel mammalian expressed human immunodeficiency virus envelope protein antigens |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5292646A (en) * | 1991-02-06 | 1994-03-08 | Genetics Institute, Inc. | Peptide and protein fusions to thioredoxin and thioredoxin-like molecules |
| US6039957A (en) | 1993-12-10 | 2000-03-21 | United States Of America, As Represented By The Department Of Health And Human Services | Oligomeric HIV-1 envelope glycoproteins |
| ATE435034T1 (de) * | 1998-08-04 | 2009-07-15 | Jackson H M Found Military Med | Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist. |
| WO2001019958A2 (en) * | 1999-09-17 | 2001-03-22 | Dana-Farber Cancer Institute, Inc. | Stabilized soluble glycoprotein trimers |
| WO2003077838A2 (en) | 2002-03-05 | 2003-09-25 | National Institutes Of Health Office Of Technology Transfer | Hiv-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and immunogens |
| AU2005280004B2 (en) * | 2004-08-27 | 2012-02-23 | Institute Of Tropical Medicine | Modified HIV-1 envelope proteins |
-
2008
- 2008-11-12 CA CA2705373A patent/CA2705373A1/en not_active Abandoned
- 2008-11-12 US US12/742,272 patent/US8597658B2/en not_active Expired - Fee Related
- 2008-11-12 EP EP08872458A patent/EP2235065A4/en not_active Withdrawn
- 2008-11-12 WO PCT/US2008/083190 patent/WO2009102357A2/en not_active Ceased
- 2008-11-12 AU AU2008350273A patent/AU2008350273B2/en not_active Ceased
- 2008-11-12 JP JP2010533337A patent/JP2011502521A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008350273A1 (en) | 2009-08-20 |
| AU2008350273B2 (en) | 2014-04-10 |
| US20100316661A1 (en) | 2010-12-16 |
| EP2235065A4 (en) | 2011-09-28 |
| WO2009102357A3 (en) | 2009-10-22 |
| JP2011502521A (ja) | 2011-01-27 |
| EP2235065A2 (en) | 2010-10-06 |
| WO2009102357A2 (en) | 2009-08-20 |
| US8597658B2 (en) | 2013-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12344661B2 (en) | Molecular complex for targeting antigens towards cells comprising antigens and uses thereof for vaccination | |
| ES2635080T3 (es) | Vacunas contra el cáncer dirigidas a células presentadoras de antígenos | |
| JP6735269B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| JP7094103B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| JP6643981B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| US20210009640A1 (en) | Compositions comprising hiv envelopes to induce hiv-1 antibodies | |
| AU2018202997A1 (en) | DNA antibody constructs and method of using same | |
| CN111542534B (zh) | 新型支架式hiv-1疫苗免疫原 | |
| EP2877205A2 (en) | Multimeric fusion protein vaccine and immunotherapeutic | |
| CN105792842A (zh) | 埃巴病毒疫苗 | |
| US20210379178A1 (en) | Compositions comprising hiv envelopes to induce hiv-1 antibodies | |
| US20190031721A1 (en) | Soluble Forms of Hendra and Nipah Virus F Glycoprotein and Uses Thereof | |
| PH12015500890B1 (en) | Vaccine for preventing porcine edema disease | |
| AU2008350273B2 (en) | HIV-1 envelope glycoprotein oligomer and methods of use | |
| KR20190079628A (ko) | 백신으로 사용하기 위한 엑소좀-앵커링 단백질을 발현하는 뉴클레오티드 서열 | |
| US20240307524A1 (en) | Coronavirus vaccines | |
| US8475799B2 (en) | HIV-1 GP41 neutralization domain and use thereof | |
| AU2013276968B2 (en) | Soluble Forms of Hendra and Nipah Virus F Glycoprotein and Uses Thereof | |
| JP4549666B2 (ja) | 抗体の製造方法 | |
| EP3104884B1 (en) | A new non-hiv vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against hiv infection | |
| JP2020162607A (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| AU2016222452A1 (en) | Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20131108 |
|
| FZDE | Discontinued |
Effective date: 20160819 |